These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 924518)

  • 21. [Formation of classical C3 convertase during the alternative pathway of human complement activation].
    Kozlov LV; Shibanova ED; Zinchenko AA
    Biokhimiia; 1987 Apr; 52(4):660-6. PubMed ID: 3647798
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Purification of chicken C3 and a structural and functional characterization.
    Laursen I; Koch C
    Scand J Immunol; 1989 Nov; 30(5):529-38. PubMed ID: 2587932
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Isolation and characterization of complement component C3 from Atlantic cod (Gadus morhua L.) and Atlantic halibut (Hippoglossus hippoglossus L.).
    Lange S; Dodds AW; Magnadóttir B
    Fish Shellfish Immunol; 2004 Feb; 16(2):227-39. PubMed ID: 15123326
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A complement-resistant HeLa cell line (T638) is blocked at the step of C3 deposition.
    Santi P; Joiner KA; Hammer CH; Frank MM; Tosi R
    J Immunol; 1987 May; 138(10):3385-91. PubMed ID: 2952716
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A cleavage product of mouse C3 adsorbable to (1----3)-beta-D-glucan from Alcaligenes faecalis var. myxogenes IFO 13140.
    Matsushita M; Sankawa U; Okuda T; Okada H; Sasaki T
    Jpn J Exp Med; 1983 Oct; 53(5):219-25. PubMed ID: 6206261
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Partial characterization of physiologically generated C3 components expressing C3d but not C3c epitopes.
    Siersted HC; Jensenius JC; Svehag SE; Brandslund I
    J Clin Lab Immunol; 1983 Dec; 12(4):201-8. PubMed ID: 6198522
    [TBL] [Abstract][Full Text] [Related]  

  • 27. C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase.
    Daha MR; Fearon DT; Austen KF
    J Immunol; 1976 Jan; 116(1):1-7. PubMed ID: 1245733
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of three monoclonal antibodies against C3 with selective specificities.
    Iida K; Mitomo K; Fujita T; Tamura N
    Immunology; 1987 Nov; 62(3):413-7. PubMed ID: 2444528
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of complement-dependent lymphocyte rosette formation by sera of patients with chronic glomerulonephritis.
    Gluckman JC; Beaufils H; Sanchez F
    Clin Exp Immunol; 1976 Nov; 26(2):247-52. PubMed ID: 991456
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A covalent dimer of complement C4b serves as a subunit of a novel C5 convertase that involves no C3 derivatives.
    Masaki T; Matsumoto M; Yasuda R; Levine RP; Kitamura H; Seya T
    J Immunol; 1991 Aug; 147(3):927-32. PubMed ID: 1861081
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Disruption of the internal thioester bond in the third component of complement (C3) results in the exposure of neodeterminants also present on activation products of C3. An analysis with monoclonal antibodies.
    Hack CE; Paardekooper J; Smeenk RJ; Abbink J; Eerenberg AJ; Nuijens JH
    J Immunol; 1988 Sep; 141(5):1602-9. PubMed ID: 2457622
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lymphocytes stimulated by allogeneic B cell lines cleave the third component of complement and fix C3 fragments. Their nonspecific lytic capacity is elevated against complement receptor type 2-carrying targets.
    Ramos OF; Algarra I; Sármay G; Yefenof E; Gergely J; Klein E
    J Immunol; 1989 Jan; 142(1):217-23. PubMed ID: 2521233
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Estimation of postmortem interval based on the third component of complement (C3) cleavage.
    Kominato Y; Harada S; Yamazaki K; Misawa S
    J Forensic Sci; 1988 Mar; 33(2):404-9. PubMed ID: 3373157
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Isolation and characterization of the third component of bovine complement.
    Menger M; Aston WP
    Vet Immunol Immunopathol; 1985 Dec; 10(4):317-31. PubMed ID: 3832572
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Purification and characterization of human and mouse complement C3.
    Ruseva MM; Heurich M
    Methods Mol Biol; 2014; 1100():75-91. PubMed ID: 24218251
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Isolation of the third component of mouse complement.
    Gyöngyössy MI; Assimeth SN
    J Immunol; 1977 Mar; 118(3):1032-5. PubMed ID: 845430
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Purification of the third component of canine complement.
    Johnson JP; Hammer CH; Winkelstein JA
    Vet Immunol Immunopathol; 1985 Apr; 8(4):377-89. PubMed ID: 4002610
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metabolic studies of C3 in man.
    Brinch L; Teisberg P; Aakesson I
    J Immunol Methods; 1979; 30(1):69-75. PubMed ID: 512363
    [TBL] [Abstract][Full Text] [Related]  

  • 39. C3e: an acidic fragment of human C3 with leukocytosis-inducing activity.
    Ghebrehiwet B; Müller-Eberhard HJ
    J Immunol; 1979 Aug; 123(2):616-21. PubMed ID: 110877
    [No Abstract]   [Full Text] [Related]  

  • 40. Demonstration of antigenic determinants specific for the split products of the third complement factor, C3.
    Sinosich MJ; Best N; Teisner B; Grudzinskas JG
    J Immunol Methods; 1982; 51(3):355-8. PubMed ID: 6180028
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.